Literature DB >> 12921784

Determinants for the interaction between Janus kinase 2 and protein phosphatase 2A.

Noriko Yokoyama1, Nancy C Reich, W Todd Miller.   

Abstract

We have shown that the serine/threonine protein phosphatase 2A (PP2A) associates with the Jak2 tyrosine kinase in a myeloid progenitor line. In this study, we characterized the regions of Jak2 and PP2A responsible for association and evaluated the functional consequences of association. We demonstrate that PP2A interacts with truncated forms of Jak2 containing the JH1 catalytic domain. Using GST fusion proteins, we show that the isolated JH1 and JH3 domains of Jak2 bind directly to PP2A. Jak2 contains putative PP2A binding sequences (LXXLL) in the JH1 domain (residues 1078-1082) and in the JH3 domain (residues 474-478). Mutation of the LXXLL sequence in the JH1 domain decreased PP2A binding in vitro, while mutation of the similar JH3 sequence did not affect PP2A binding. We analyzed full-length Jak2 bearing the LXXLL mutation in Cos-7 cells for association with PP2A. The JH1 mutation impaired Jak2 activity and had a modest effect on PP2A binding. Finally, we show that a mutant form of the PP2A catalytic subunit lacking a site for phosphorylation (Y307F) binds more tightly to Jak2 than wild-type PP2A, consistent with a model where phosphorylation disrupts the Jak2-PP2A interaction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12921784     DOI: 10.1016/s0003-9861(03)00333-3

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  8 in total

Review 1.  Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.

Authors:  Danilo Perrotti; Giovannino Silvestri; Lorenzo Stramucci; Justine Yu; Rossana Trotta
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

2.  Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.

Authors:  A K Samanta; S N Chakraborty; Y Wang; H Kantarjian; X Sun; J Hood; D Perrotti; R B Arlinghaus
Journal:  Oncogene       Date:  2009-02-23       Impact factor: 9.867

Review 3.  JAK redux: a second look at the regulation and role of JAKs in the heart.

Authors:  Mazen Kurdi; George W Booz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-28       Impact factor: 4.733

4.  Insulin receptor substrates are essential for the bioenergetic and hypertrophic response of the heart to exercise training.

Authors:  Christian Riehle; Adam R Wende; Yi Zhu; Karen J Oliveira; Renata O Pereira; Bharat P Jaishy; Jack Bevins; Steven Valdez; Junghyun Noh; Bum Jun Kim; Annie Bello Moreira; Eric T Weatherford; Rajkumar Manivel; Tenley A Rawlings; Monika Rech; Morris F White; E Dale Abel
Journal:  Mol Cell Biol       Date:  2014-07-07       Impact factor: 4.272

5.  Protein phosphatase 2A interacts with the Na,K-ATPase and modulates its trafficking by inhibition of its association with arrestin.

Authors:  Toru Kimura; Wonsun Han; Philipp Pagel; Angus C Nairn; Michael J Caplan
Journal:  PLoS One       Date:  2011-12-29       Impact factor: 3.240

6.  The SH2 domain and kinase activity of JAK2 target JAK2 to centrosome and regulate cell growth and centrosome amplification.

Authors:  Aashirwad Shahi; Jacob Kahle; Chandler Hopkins; Maria Diakonova
Journal:  PLoS One       Date:  2022-01-28       Impact factor: 3.752

Review 7.  Chronic myeloid leukemia stem cells: targeting therapeutic implications.

Authors:  Hanieh Mojtahedi; Niloufar Yazdanpanah; Nima Rezaei
Journal:  Stem Cell Res Ther       Date:  2021-12-18       Impact factor: 6.832

8.  Investigation of PP2A and Its Endogenous Inhibitors in Neuroblastoma Cell Survival and Tumor Growth.

Authors:  Adele P Williams; Evan F Garner; Alicia M Waters; Laura L Stafman; Jamie M Aye; Hooper Markert; Jerry E Stewart; Elizabeth A Beierle
Journal:  Transl Oncol       Date:  2018-10-01       Impact factor: 4.243

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.